A detailed history of Ifp Advisors, Inc transactions in Altimmune, Inc. stock. As of the latest transaction made, Ifp Advisors, Inc holds 200 shares of ALT stock, worth $1,650. This represents 0.0% of its overall portfolio holdings.

Number of Shares
200
Holding current value
$1,650
% of portfolio
0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 30, 2024

BUY
$5.91 - $10.23 $1,182 - $2,046
200 New
200 $1,000
Q3 2021

Oct 06, 2021

SELL
$8.43 - $16.81 $18,773 - $37,435
-2,227 Closed
0 $0
Q2 2021

Jul 13, 2021

SELL
$9.85 - $16.46 $23,364 - $39,043
-2,372 Reduced 51.58%
2,227 $20,000
Q1 2021

Apr 30, 2021

SELL
$12.71 - $24.31 $50,166 - $95,951
-3,947 Reduced 46.19%
4,599 $66,000
Q4 2020

Jan 25, 2021

BUY
$7.84 - $14.22 $36,448 - $66,108
4,649 Added 119.3%
8,546 $97,000
Q3 2020

Oct 29, 2020

BUY
$9.93 - $33.26 $38,697 - $129,614
3,897 New
3,897 $52,000
Q1 2019

May 15, 2019

SELL
$2.54 - $4.54 $30 - $54
-12 Closed
0 $0
Q3 2018

Oct 25, 2018

BUY
$4.27 - $26.23 $51 - $314
12 New
12 $0

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $404M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Ifp Advisors, Inc Portfolio

Follow Ifp Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ifp Advisors, Inc with notifications on news.